437 results on '"Friberg, Lena E."'
Search Results
2. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
3. Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework
4. Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
5. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
6. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
7. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
8. Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
9. Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1
10. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
11. Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
12. Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
13. Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
14. Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis.
15. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
16. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
17. Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes.
18. Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections
19. Considerations for the optimal management of antibiotic therapy in elderly patients
20. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
21. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
22. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
23. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation
24. Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
25. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib.
26. Multistate modeling for survival analysis in critically ill patients treated with meropenem.
27. Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions.
28. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
29. Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies.
30. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology.
31. A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer.
32. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models.
33. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
34. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
35. Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase
36. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling
37. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data
38. A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
39. Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
40. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
41. Inter occasion variability in individual optimal design
42. Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
43. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
44. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
45. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
46. Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
47. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
48. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
49. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model
50. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.